Video

Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy

Author(s):

Karim Chamie, MD

Karim Chamie, MD, reviews the currently available adjuvant therapy options for patients with stage II or III MIBC who received a cystectomy, and whether he would have treated the patient in the presented case or referred her to a medical oncologist.

Related Videos
Interpreting ART toxicity and tolerability for bladder cancer, with Vedang Murthy, MD
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer
Related Content
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
October 11th 2024

Upper tract urothelial carcinoma: An in-depth review for urologists

Jesse Persily, MD Sameer Thakker, MD Katie S. Murray, DO, MS
"On-going innovation will continue to drive UTUC management forward, and with it will come on-going challenges of how to best study a relatively rare disease," write the authors.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Andrea Necchi, MD, on promising SunRISe-4 data of TAR-200 in MIBC
October 9th 2024

Andrea Necchi, MD, on promising SunRISe-4 data of TAR-200 in MIBC

Hannah Clarke
"Overall, TAR-200 is being tested with the aim of changing the therapeutic paradigm of patients with an early bladder cancer diagnosis, including non–muscle-invasive disease and muscle-invasive disease," says Andrea Necchi, MD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Phase 3 trial progresses of padeliporfin VTP therapy in upper tract urothelial carcinoma
September 30th 2024

Phase 3 trial progresses of padeliporfin VTP therapy in upper tract urothelial carcinoma

Hannah Clarke
The phase 3 ENLIGHTED trial has reached the 50% patient enrollment threshold.
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
September 27th 2024

3D bioprinting technology facilitates development of an in vitro biomimetic bladder model

Kate Gessner, MD, PhD Philip Abbosh, MD, PhD
"This exciting and innovative technology has a wide range of possible applications, including tissue engineering, drug development, and precision medicine," write Kate Gessner, MD, PhD, and Philip Abbosh, MD, PhD.
© 2024 MJH Life Sciences

All rights reserved.